ABSTRACT
Coagulation factor XIII (F13) circulates in blood as a heterotetramer composed of an A subunit dimer and a B subunit dimer. It is activated by thrombin and crosslinks fibrin monomers. Congenital F13 deficiency demonstrates a lifelong bleeding tendency, abnormal wound healing, and recurrent miscarriages, and it first manifests as umbilical bleeding after birth. In contrast, secondary F13 deficiencies due to its overconsumption and/or hypobiosynthesis by disseminated intravascular coagulation, major surgery, liver diseases, and other disorders are rather common but rarely complicated with bleeding symptoms. Recently, consultations with physicians who have patients with hemorrhagic-acquired F13 deficiency with anti-F13 inhibitors (acquired hemorrhaphilia 13) have indicated an increase in this disease in Japan. We performed a nationwide survey, supported by the Japanese Ministry of Health, Welfare and Labor and confirmed 21 Japanese cases of this disease with anti-F13 inhibitors. Because neither prolonged clotting times nor reduced platelet counts are observed in patients with this disease, many more cases may have been overlooked. Physicians must be mindful of acquired hemorrhaphilia 13 when seeing such patients and should measure F13 activity. Products containing F13 are effective for hemostasis generally, and immunosuppressive therapy must be started immediately to eradicate anti-F13 antibodies.
KEYWORDS
Acquired bleeding tendency - protein crosslinking enzyme - autoantibody - decreased production - increased consumption
REFERENCES
-
1 Brinkhous K M. A short history of hemophilia, with some comments on the word ‘Hemophilia’. Hemker H C, Brinkhous K M, eds. Handbook of Hemophilia. New York, NY: Excerpta Medica; 1975: 3-20
-
2
Boggio L N, Green D.
Acquired hemophilia.
Rev Clin Exp Hematol.
2001;
5
(4)
389-404
quiz 431
-
3
Collins P W, Hirsch S, Baglin T P UK Haemophilia Centre Doctors' Organisation et al.
Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation.
Blood.
2007;
109
(5)
1870-1877
-
4 Loland L. Acquired inhibitors of fibrin stabilization: a class of hemorrhagic disorders of diverse origins. In: Green D, ed. Anticoagulants: Physiologic, Pathologic & Pharmacologic. Boca Raton, FL: CRC Press; 1994: 169-191
-
5
Egbring R, Kröniger A, Seitz R.
Erworbene Inhibitoren gegen Faktor XIII.
Hamostaseologie.
1996;
16
174-179
-
6
Lorand L, Losowsky M S, Miloszewski K J.
Human factor XIII: fibrin-stabilizing factor.
Prog Hemost Thromb.
1980;
5
245-290
-
7
Ichinose A.
Extracellular transglutaminase: factor XIII.
Prog Exp Tumor Res.
2005;
38
192-208
-
8
AbdAlla S, Lother H, Langer A, el Faramawy Y, Quitterer U.
Factor XIIIA transglutaminase crosslinks AT1 receptor dimers of monocytes at the onset of atherosclerosis.
Cell.
2004;
119
(3)
343-354
-
9
Kasahara K, Souri M, Kaneda M, Miki T, Yamamoto N, Ichinose A.
Impaired clot retraction in factor XIII A subunit-deficient mice.
Blood.
2010;
115
(6)
1277-1279
-
10
Ichinose A, Asahina T, Kobayashi T.
Congenital blood coagulation factor XIII deficiency and perinatal management.
Curr Drug Targets.
2005;
6
(5)
541-549
-
11
Seitz R, Duckert F, Lopaciuk S, Muszbek L, Rodeghiero F, Seligsohn U. Study Group .
ETRO Working Party on Factor XIII questionnaire on congenital factor XIII deficiency in Europe: status and perspectives.
Semin Thromb Hemost.
1996;
22
(5)
415-418
-
12
Gerlach R, Raabe A, Zimmermann M, Siegemund A, Seifert V.
Factor XIII deficiency and postoperative hemorrhage after neurosurgical procedures.
Surg Neurol.
2000;
54
(3)
260-264
discussion 264-265
-
13
Korte W F.
F. XIII in perioperative coagulation management.
Best Pract Res Clin Anaesthesiol.
2010;
24
(1)
85-93
-
14
Ivaskevicius V, Biswas A, Loreth R et al..
Mutations affecting disulphide bonds contribute to a fairly common prevalence of F13B gene defects: results of a genetic study in 14 families with factor XIII B deficiency.
Haemophilia.
2010;
16
(4)
675-682
-
15
Ajzner E, Schlammadinger A, Kerényi A et al..
Severe bleeding complications caused by an autoantibody against the B subunit of plasma factor XIII: a novel form of acquired factor XIII deficiency.
Blood.
2009;
113
(3)
723-725
-
16
Ajzner E, Muszbek L.
Kinetic spectrophotometric factor XIII activity assays: the subtraction of plasma blank is not omissible [corrected].
J Thromb Haemost.
2004;
2
(11)
2075-2077
-
17
Caudill J S, Nichols W L, Plumhoff E A et al..
Comparison of coagulation factor XIII content and concentration in cryoprecipitate and fresh-frozen plasma.
Transfusion.
2009;
49
(4)
765-770
-
18
Ishida F, Okubo K, Ito T, Okumura N, Souri M, Ichinose A.
Spontaneous regression of the inhibitor against the coagulation factor XIII A subunit in acquired factor XIII deficiency.
Thromb Haemost.
2010;
104
(6)
1284-1285
-
19
Ballerini G, Guerra S, Rodeghiero F, Castaman G.
A contribution to the pathology of acquired plasma factor XIII deficiency.
Semin Thromb Hemost.
1985;
11(4)
357-361
-
20
Egbring R, Kröniger A, Seitz R.
Factor XIII deficiency: pathogenic mechanisms and clinical significance.
Semin Thromb Hemost.
1996;
22
(5)
419-425
-
21
Ichinose A, Souri M.
on behalf of the Japanese Collaborative Research Group on “Acquired haemorrhaphilia due to factor XIII deficiency”. As many as 12 cases with haemorrhagic acquired factor XIII deficiency due to its inhibitors were recently found in Japan.
Thromb Haemost.
2011;
105
(5)
925-927
-
22
Jennings I, Kitchen S, Woods T A, Preston F E. UK NEQAS .
Problems relating to the laboratory diagnosis of factor XIII deficiency: a UK NEQAS study.
J Thromb Haemost.
2003;
1
(12)
2603-2608
Akitada IchinoseM.D. Ph.D.
Professor and Chairman, Department of Mol. Patho-Biochem. & -Biolo., Yamagata University School of Medicine
2-2-2 Iida-Nishi, Yamagata, 990-9585 Japan
eMail: aichinos@med.id.yamagata-u.ac.jp
